Coverage
-
March 02, 2026
BioXcel Therapeutics Inc., an artificial intelligence-driven drugmaker, has reached a $9.8 million settlement with investors to resolve claims that the company and its top brass deceived them about compliance problems with a clinical trial for a dementia drug.
8 other articles on this case.
View all »